By Professor Elgene Lim

Journal articles

Chen J; Colosimo M; Lim E, 2021, 'The management of HER2-positive early breast cancer: Current and future therapies', Asia Pacific Journal of Clinical Oncology, 17, pp. 3 - 12, http://dx.doi.org/10.1111/ajco.13655

Ardolino L; Lau B; Wilson I; Chen J; Borella L; Stone E; Lim E, 2021, 'Case Report: Paclitaxel-Induced Pneumonitis in Early Breast Cancer: A Single Institution Experience and Review', Frontiers in Oncology, 11, http://dx.doi.org/10.3389/fonc.2021.701424

Jhaveri KL; Lim E; Hamilton EP; Saura C; Meniawy T; Jeselsohn R; Beck JT; Kaufman PA; Sammons S; Banda K; Okera M; Yonemori K; Harnden KK; Kim S-B; Sohn J; X. C; Aftimos PG; Wang XA; Young SRL; Beeram M, 2021, 'A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.', Journal of Clinical Oncology, 39, pp. 1050 - 1050, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.1050

Martin M; Lim E; Mac Gregor MC; Shivhare M; Ross G; Patre M; Roncoroni L; Louka M; Sohn J, 2021, 'acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician’s choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).', Journal of Clinical Oncology, 39, pp. tps1100 - tps1100, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.tps1100

Wong V; de Boer R; Baron-Hay SE; Blum RH; Forster BC; Chua SLL; Cuff K; Green M; Lim E; Mok K; Nott LM; Nottage MK; Tafreshi A; Tsoi DTF; Yeo B; Gibbs P; Lok SW, 2021, 'Australian real-world outcomes of ribociclib and aromatase inhibitor in hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC): Results from Kisqali Access Registry for Metastatic breast cancer in Australia (KARMA) collected alongside a medicine access program.', Journal of Clinical Oncology, 39, pp. e13018 - e13018, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e13018

Palmieri C; Linden HM; Birrell S; Lim E; Schwartzberg LS; Rugo HS; Cobb PW; Jain K; Vogel CL; O'Shaughnessy J; Johnston SRD; Getzenberg RH; Barnette KG; Steiner MS; Brufsky A; Overmoyer B, 2021, 'Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study.', Journal of Clinical Oncology, 39, pp. 1020 - 1020, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.1020

Jhaveri KL; Boni V; Sohn J; Villanueva-Vásquez R; Bardia A; Schmid P; Lim E; Patel JM; Perez-Fidalgo JA; Loi S; Im S-A; Kshirsagar S; Gates MR; Bond J; Eng-Wong J; Chang C-W; Turner NC; Miranda EL; García-Estévez L; Bellet M, 2021, 'Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC).', Journal of Clinical Oncology, 39, pp. 1017 - 1017, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.1017

Freelander A; Brown LJ; Parker A; Segara D; Portman N; Lau B; Lim E, 2021, 'Molecular biomarkers for contemporary therapies in hormone receptor‐positive breast cancer', Genes, 12, pp. 1 - 24, http://dx.doi.org/10.3390/genes12020285

Hickey TE; Selth LA; Chia KM; Laven-Law G; Milioli HH; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell SN; Stelloo S; Iggo R; Alexandrou S; Caldon CE; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Lim E; Carroll JS; Tilley WD, 2021, 'The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer', Nature Medicine, 27, pp. 310 - 320, http://dx.doi.org/10.1038/s41591-020-01168-7

Hui R; de Boer R; Lim E; Yeo B; Lynch J, 2021, 'CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care', Asia Pacific Journal of Clinical Oncology, 17, pp. 3 - 14, http://dx.doi.org/10.1111/ajco.13555

Chia KM; Freelander A; Kumar S; Parker A; Segara D; Portman N; Lim E, 2020, 'Estrogen receptor positive breast cancer patient–derived xenograft models in translational research', Current Opinion in Endocrine and Metabolic Research, 15, pp. 31 - 36, http://dx.doi.org/10.1016/j.coemr.2020.10.004

de Boer R; Hui R; Lim E; Yeo B; Zdenkowski N, 2020, 'Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer', Asia Pacific Journal of Clinical Oncology, 16, pp. 3 - 14, http://dx.doi.org/10.1111/ajco.13461

Wu SZ; Roden DL; Wang C; Holliday H; Harvey K; Cazet AS; Murphy KJ; Pereira B; Al-Eryani G; Bartonicek N; Hou R; Torpy JR; Junankar S; Chan CL; Lam CE; Hui MN; Gluch L; Beith J; Parker A; Robbins E; Segara D; Mak C; Cooper C; Warrier S; Forrest A; Powell J; O'Toole S; Cox TR; Timpson P; Lim E; Liu XS; Swarbrick A, 2020, 'Stromal cell diversity associated with immune evasion in human triple-negative breast cancer', EMBO Journal, 39, pp. embj2019104063, http://dx.doi.org/10.15252/embj.2019104063

Light M; McFarlane T; Ives A; Shah B; Lim E; Grossmann M; Zajac JD; Cheung AS, 2020, 'Testosterone therapy considerations in oestrogen, progesterone and androgen receptor–positive breast cancer in a transgender man', Clinical Endocrinology, 93, pp. 355 - 357, http://dx.doi.org/10.1111/cen.14263

Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E, 2020, 'MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer', Breast Cancer Research, 22, pp. 87, http://dx.doi.org/10.1186/s13058-020-01318-2

Baker LA; Holliday H; Roden D; Krisp C; Wu SZ; Junankar S; Serandour AA; Mohammed H; Nair R; Sankaranarayanan G; Law AMK; McFarland A; Simpson PT; Lakhani S; Dodson E; Selinger C; Anderson L; Samimi G; Hacker NF; Lim E; Ormandy CJ; Naylor MJ; Simpson K; Nikolic I; O'Toole S; O'Toole S; O'Toole S; O'Toole S; Kaplan W; Cowley MJ; Carroll JS; Molloy M; Swarbrick A, 2020, 'Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer', Breast Cancer Research, 22, http://dx.doi.org/10.1186/s13058-020-01306-6

Lim E; Jhaveri KL; Perez-Fidalgo JA; Bellet M; Boni V; Perez Garcia JM; Estevez L; Bardia A; Turner NC; Villanueva R; Lopez-Tarruella Cobo S; Im S-A; Kim S-B; Gates MR; Monemi S; Chen Y-C; Moore H; Loi S; Sohn J, 2020, 'A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.', Journal of Clinical Oncology, 38, pp. 1023 - 1023, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1023

Tadesse S; Anshabo AT; Portman N; Lim E; Tilley W; Caldon CE; Wang S, 2020, 'Targeting CDK2 in cancer: challenges and opportunities for therapy', Drug Discovery Today, 25, pp. 406 - 413, http://dx.doi.org/10.1016/j.drudis.2019.12.001

Milioli HH; Alexandrou S; Lim E; Caldon CE, 2020, 'Cyclin E1 and cyclin E2 in ER+ breast cancer: Prospects as biomarkers and therapeutic targets', Endocrine Related Cancer, 27, pp. R93 - R112, http://dx.doi.org/10.1530/ERC-19-0501

Chen J; Easwaralingam N; Warrier S; Ong A; Carson EK; Mak C; Snook K; Middleton K; Parker A; Palmieri C; Spillane A; Mann GB; Lim E; Segara D, 2020, 'Window of opportunity treatment in breast cancer', ANZ Journal of Surgery, 90, pp. 34 - 40, http://dx.doi.org/10.1111/ans.15487

Yang Y; Cooper C; Robbins E; Swarbrick A; Harvey K; Lim E; Mak C; Carmalt H; Warrier S; Chan B; Beith J; Hui M; Gluch L; O’Toole S; Cooper W, 2020, '9. Factors influencing the success rate of patient derived xenograft formation from breast cancer specimens', Pathology, 52, pp. s136, http://dx.doi.org/10.1016/j.pathol.2020.01.010

Kim S-B; Keam B; Shin S; Chae YS; Seo S; Park K; Kim TM; Park LC; Hong S-B; Lim E; Lee S; Ahn M-J, 2020, 'Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)', Annals of Oncology, 31, pp. s667 - s668, http://dx.doi.org/10.1016/j.annonc.2020.08.1043

Thompson EJ; Duluc C; Barry EF; Farshid G; Simpson KJ; Gregory PA; Li X; Madden S; Owczarek CM; Wilson NJ; Vairo G; Nash AD; Ingman WV; Lindeman GJ; Lim E; Khew-Goodall Y; Lopez AF; Bonder CS, 2019, 'Expression of the interleukin-3/receptor complex by breast cancer cells promotes vascular mimicry via a PI3K-dependent mechanism and is associated with poor outcome', Oncology Abstracts, http://dx.doi.org/10.1530/oncolabs.1.p005

Roden D; Wu S; Harvey K; Chan C-L; Al-Eryani G; Cazet A; Lim E; Swarbrick A, 2019, 'Single-cell transcriptomics reveals marked heterogeneity for intrinsic molecular subtype and cellular function in estrogen receptor positive breast cancer', Oncology Abstracts, http://dx.doi.org/10.1530/oncolabs.1.p045

Juan BPS; Zadeh S; Ganju V; Vargas C; O'Toole S; Lim E; Davis M; Chaffer C, 2019, 'Unravelling the role of cell plasticity in BrCa development and metastasis', Oncology Abstracts, http://dx.doi.org/10.1530/oncolabs.1.p040

Grossmann M; Ramchand SK; Milat F; Vincent A; Lim E; Kotowicz MA; Hicks J; Teede HJ, 2019, 'Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary', Medical Journal of Australia, 211, pp. 224 - 229, http://dx.doi.org/10.5694/mja2.50280

Field AS; Raymond WA; Rickard M; Arnold L; Brachtel EF; Chaiwun B; Chen L; Di Bonito L; Kurtycz DFI; Lee AHS; Lim E; Ljung BM; Michelow P; Osamura RY; Pinamonti M; Sauer T; Segara D; Tse G; Vielh P; Chong PY; Schmitt F, 2019, 'The international academy of cytology yokohama system for reporting breast fine-needle aspiration biopsy cytopathology', Acta Cytologica, 63, pp. 257 - 273, http://dx.doi.org/10.1159/000499509

Young AR; Duarte JDG; Coulson R; O’brien M; Deb S; Lopata A; Behren A; Mathivanan S; Lim E; Meeusen E, 2019, 'Immunoprofiling of breast cancer antigens using antibodies derived from local lymph nodes', Cancers, 11, http://dx.doi.org/10.3390/cancers11050682

Kennedy SP; Han JZR; Portman N; Nobis M; Hastings JF; Murphy KJ; Latham SL; Cadell AL; Miladinovic D; Marriott GR; O'Donnell YEI; Shearer RF; Williams JT; Munoz AG; Cox TR; Watkins DN; Saunders DN; Timpson P; Lim E; Kolch W; Croucher DR, 2019, 'Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer', Breast Cancer Research, 21, http://dx.doi.org/10.1186/s13058-019-1127-y

Lee KWC; Lord S; Finn RS; Lim E; Martin A; Loi S; Lynch J; Friedlander M; Lee CK, 2019, 'The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis', Breast Cancer Research and Treatment, 174, pp. 271 - 278, http://dx.doi.org/10.1007/s10549-018-5054-x

Chia KM; Milioli H; Portman N; Laven-Law G; Coulson R; Yong A; Segara D; Parker A; Caldon CE; Deng N; Swarbrick A; Tilley WD; Hickey TE; Lim E, 2019, 'Non-canonical AR activity facilitates endocrine resistance in breast cancer', Endocrine Related Cancer, 26, pp. 251 - 264, http://dx.doi.org/10.1530/ERC-18-0333

Chi D; Singhal H; Li L; Xiao T; Liu W; Pun M; Jeselsohn R; He H; Lim E; Vadhi R; Rao P; Long H; Garber J; Brown M, 2019, 'Estrogen receptor signaling is reprogrammed during breast tumorigenesis', Proceedings of the National Academy of Sciences of the United States of America, 166, pp. 11437 - 11443, http://dx.doi.org/10.1073/pnas.1819155116

Portman N; Alexandrou S; Carson E; Wang S; Lim E; Caldon CE, 2019, 'Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer', Endocrine Related Cancer, 26, pp. R15 - R30, http://dx.doi.org/10.1530/ERC-18-0317

Field AS; Schmitt F; Raymond F, 2019, 'The IAC Yokohama system for reporting breast FNAB cytology', Acta Cytologica, 63, pp. 257 - 273, http://dx.doi.org/10.1159/000499509

Alexandrou S; George SM; Ormandy CJ; Lim E; Oakes SR; Elizabeth Caldon C, 2019, 'The proliferative and apoptotic landscape of basal-like breast cancer', International Journal of Molecular Sciences, 20, http://dx.doi.org/10.3390/ijms20030667

Papachristou EK; Kishore K; Holding AN; Harvey K; Roumeliotis TI; Chilamakuri CSR; Omarjee S; Chia KM; Swarbrick A; Lim E; Markowetz F; Eldridge M; Siersbaek R; D’Santos CS; Carroll JS, 2018, 'A quantitative mass spectrometry-based approach to monitor the dynamics of endogenous chromatin-associated protein complexes', Nature Communications, 9, http://dx.doi.org/10.1038/s41467-018-04619-5

Cazet AS; Hui MN; Elsworth BL; Wu SZ; Roden D; Chan CL; Skhinas JN; Collot R; Yang J; Harvey K; Johan MZ; Cooper C; Nair R; Herrmann D; McFarland A; Deng N; Ruiz-Borrego M; Rojo F; Trigo JM; Bezares S; Caballero R; Lim E; Timpson P; O’Toole S; Watkins DN; Cox TR; Samuel MS; Martín M; Swarbrick A; O'Toole S, 2018, 'Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer', Nature Communications, 9, pp. 2897, http://dx.doi.org/10.1038/s41467-018-05220-6

Galimberti V; Cole BF; Viale G; Veronesi P; Vicini E; Intra M; Mazzarol G; Massarut S; Zgajnar J; Taffurelli M; Littlejohn D; Knauer M; Tondini C; Di Leo A; Colleoni M; Regan MM; Coates AS; Gelber RD; Goldhirsch A; Boyle F; Jerusalem G; Stahel R; Aebi S; Green M; Karlsson P; Kössler I; Láng I; Hiltbrunner A; Bernhard J; Fournarakou S; Kammler R; Maibach R; Rabaglio M; Ribi K; Roschitzki H; Roux S; Ruepp B; Mahoney C; Price K; Blacher L; Scolese T; Scott K; Lippert S; Zielinski T; Mastropasqua M; Andrighetto S; Dell'orto P; Renne G; Pruneri G; Dellapasqua S; Iorfida M; Cancello G; Montagna E; Cardillo A; Peruzzotti G; Ghisini R; Luini A; Veronesi U; Gentilini O; Zurrida S; Curigliano G; Nole F; Orecchia R; Cristina Leonardi M; Baratella P; Chifu C; Sargenti M; Crivellari D; Morassut S; Mileto M; Piccoli E; Veronesi A; Donatella Magri M; Buonadonna A; Candiani E; Carbone A; Perin T; Volpe R; Roncadin M; Arcicasa M; Coran F; Lagrassa M; Recalcati A; Emanuela Limonta M; Tricomi P; Fenaroli P; Candiago E; Cattaneo L; Gianatti A; Santini D; Maweja S; Delvenne P; Rorive A; Collignon J; Garbay JR; Mathieu MC; Galatius H; Hoffmann J; Schousen P; Lanng C, 2018, 'Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial', Lancet Oncology, 19, pp. 1385 - 1393, http://dx.doi.org/10.1016/S1470-2045(18)30380-2

Lim E; Beith J; Boyle F; de Boer R; Hui R; McCarthy N; Redfern A; Wade T; Woodward N, 2018, 'Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer', Asia Pacific Journal of Clinical Oncology, 14, pp. 12 - 21, http://dx.doi.org/10.1111/ajco.13065

Boyle F; Beith J; Burslem K; de Boer R; Hui R; Lim E; McCarthy N; Redfern A; Woodward N, 2018, 'Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm', Asia Pacific Journal of Clinical Oncology, 14, pp. 3 - 11, http://dx.doi.org/10.1111/ajco.13064

Grossmann M; Ramchand SK; Milat F; Vincent A; Lim E; Kotowicz MA; Hicks J; Teede H, 2018, 'Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia', Clinical Endocrinology, 89, pp. 280 - 296, http://dx.doi.org/10.1111/cen.13735

Robinson DH; Churilov L; Lin NU; Lim E; Seah D, 2018, 'Attitudes of patients with metastatic cancer towards research biopsies', Asia Pacific Journal of Clinical Oncology, 14, pp. 231 - 238, http://dx.doi.org/10.1111/ajco.12783

Roswall P; Bocci M; Bartoschek M; Li H; Kristiansen G; Jansson S; Lehn S; Sjölund J; Reid S; Larsson C; Eriksson P; Anderberg C; Cortez E; Saal LH; Orsmark-Pietras C; Cordero E; Haller BK; Häkkinen J; Burvenich IJG; Lim E; Orimo A; Höglund M; Rydén L; Moch H; Scott AM; Eriksson U; Pietras K, 2018, 'Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling', Nature Medicine, 24, pp. 463 - 473, http://dx.doi.org/10.1038/nm.4494

Wang Y; Li YM; Baitsch L; Huang A; Xiang Y; Tong H; Lako A; Von T; Choi C; Lim E; Min J; Li L; Stegmeier F; Schlegel R; Eck MJ; Gray NS; Mitchison TJ; Zhao JJ, 2018, 'Erratum: Correction: MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells (eLife (2014) 3 (e01763) PII: e36414)', Elife, 7, http://dx.doi.org/10.7554/eLife.36414

Hastie R; Lim E; Sluka P; Campbell L; Horne AW; Ellett L; Hannan NJ; Brownfoot F; Kaitu'u-Lino TJ; Tong S, 2018, 'Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy', Ebiomedicine, 29, pp. 166 - 176, http://dx.doi.org/10.1016/j.ebiom.2018.01.041

Metzger-Filho O; Mandrekar S; Loibl S; Ciruelos E; Gianni L; Lim E; Miller K; Huang C; Koehler M; Francis P; Valagussa P; Goel S; Prat A; Goetz M; Loi S; Krop I; Carey L; Lanzillotti J; Winer E; Tripathy D; DeMichele A, 2018, 'PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer', CANCER RESEARCH, 78

Lim E; Portman N; Wahlroos S; Parker A; Segara D, 2017, 'Endocrine therapy for breast cancer: A Renaissance', The Endocrinologist, pp. 13 - 14

Meeusen E; Lim E; Mathivanan S, 2017, 'Secreted Tumor Antigens – Immune Biomarkers for Diagnosis and Therapy', Proteomics, 17, http://dx.doi.org/10.1002/pmic.201600442

Lim E; Johnson SF; Geyer M; Serra V; Shapiro GI, 2017, 'Sensitizing HR-proficient cancers to PARP inhibitors', Molecular and Cellular Oncology, 4, http://dx.doi.org/10.1080/23723556.2017.1299272

Brockwell NK; Owen KL; Zanker D; Spurling A; Rautela J; Duivenvoorden HM; Baschuk N; Caramia F; Loi S; Darcy PK; Lim E; Parker BS, 2017, 'Neoadjuvant interferons: Critical for effective PD-1–based immunotherapy in TNBC', Cancer Immunology Research, 5, pp. 871 - 884, http://dx.doi.org/10.1158/2326-6066.CIR-17-0150

Back to profile page